Abstract
Abstract Background: Hepatoblastoma (HB) is an embryonal tumor of the liver that occurs in infants and young children. Complete surgical resection and cisplatin-containing chemotherapy are crucial for cure in HB. Cancer stem cells (CSCs) constitute a newly identified subpopulation, which may differentiate into heterogeneous progenies of malignant cells. The aim of this study is to assess the prognostic and predictive values of CSCs markers (CD133, CD90 and CD44) in a cohort of HB patients from Egypt. Methods: Disease status was evaluated for 43 HB patients at the main checkpoints of therapy and during follow-up. Protein and RNA expressions of CD44, CD 90 and CD 133 were assessed by immunohistochemistry and quantitative real time (qPCR). Results: OS for all patients at 4 years was 58.2. OS significantly correlated with disease stages (stage I&II versus III&IV 81.9% and 30%, p<0.001); tumor response (p<0.001); CD44, CD 90, CD 133 expression (p<0.001) versus treatment modality (total surgical resection versus incomplete or no resection, 83.8% versus 25.2 %; p<0.001). Reduced DFS was associated with CD44 and CD133 expression (p<0.001) only. Conclusion: Complete surgical resection and systemic chemotherapy significantly improve outcome in HB with a significantly higher survival rates among patients with early stage disease. Expression of CSCs markers (CD133, 44, and 90) can predict poor outcome in HB patients with reduced OS and DFS rates. However further studies are required to confirm their prognostic and potential targeted therapy value. Citation Format: Abdel-Rahman N. Zekri, Abeer A. Bahnassy, Mohamed Fawzy, Mohamed El-Wakil, Ahmed Abdel-Sayed, Marwa E. Sheta. Increased expression of cancer stem cells markers (CD44, CD90 and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients from Egypt: four years survival data. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3991. doi:10.1158/1538-7445.AM2014-3991
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
